Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02443324
Title A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

ureter transitional cell carcinoma

lung non-small cell carcinoma

gastric adenocarcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

gastroesophageal junction adenocarcinoma

Therapies

Pembrolizumab + Ramucirumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.